190 related articles for article (PubMed ID: 35747987)
1. Histopathological and epigenetic changes in myocardium associated with cancer therapy-related cardiac dysfunction.
Terada CI; Onoue K; Fujii T; Itami H; Morita K; Uchiyama T; Takeda M; Nakagawa H; Nakano T; Baba Y; Amemiya K; Saito Y; Hatakeyama K; Ohbayashi C
ESC Heart Fail; 2022 Oct; 9(5):3031-3043. PubMed ID: 35747987
[TBL] [Abstract][Full Text] [Related]
2. Cancer Therapeutics-related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation.
Peleg Hasson S; Arnold J; Merdler I; Sivan A; Shamai S; Geva R; Merimsky O; Shachar E; Waissengrin B; Moshkovits Y; Arbel Y; Topilsky Y; Rozenbaum Z; Wolf I; Laufer-Perl M
J Immunother; 2021 Jun; 44(5):179-184. PubMed ID: 33950028
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.
Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B
JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442
[TBL] [Abstract][Full Text] [Related]
4. The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy.
Laufer-Perl M; Arnold JH; Mor L; Amrami N; Derakhshesh M; Moshkovits Y; Sadeh B; Arbel Y; Topilsky Y; Rozenbaum Z
Clin Res Cardiol; 2020 Feb; 109(2):255-262. PubMed ID: 31214777
[TBL] [Abstract][Full Text] [Related]
5. Activation recovery interval as an electrocardiographic repolarization index to detect doxorubicin-induced cardiotoxicity.
Kinoshita T; Onda N; Ohno R; Ikeda T; Sugizaki Y; Ohara H; Nakagami T; Yuzawa H; Shimada H; Shimizu K; Ikeda T
J Cardiol; 2023 Dec; 82(6):473-480. PubMed ID: 37506822
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity.
Calvillo-Argüelles O; Thampinathan B; Somerset E; Shalmon T; Amir E; Steve Fan CP; Moon S; Abdel-Qadir H; Thevakumaran Y; Day J; Woo A; Wintersperger BJ; Marwick TH; Thavendiranathan P
JACC Cardiovasc Imaging; 2022 Aug; 15(8):1361-1376. PubMed ID: 35926895
[TBL] [Abstract][Full Text] [Related]
7. Cancer Therapeutics-Related Cardiac Dysfunction among Patients with Active Breast Cancer: A Cardio-Oncology Registry.
Laufer-Perl M; Mor L; Milwidsky A; Derakhshesh M; Amrami N; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Rozenbaum Z
Isr Med Assoc J; 2020 Sep; 22(9):564-568. PubMed ID: 33236555
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.
Oikonomou EK; Kokkinidis DG; Kampaktsis PN; Amir EA; Marwick TH; Gupta D; Thavendiranathan P
JAMA Cardiol; 2019 Oct; 4(10):1007-1018. PubMed ID: 31433450
[TBL] [Abstract][Full Text] [Related]
9. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability.
Altaha MA; Nolan M; Marwick TH; Somerset E; Houbois C; Amir E; Yip P; Connelly KA; Michalowska M; Sussman MS; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2020 Apr; 13(4):951-962. PubMed ID: 31864977
[TBL] [Abstract][Full Text] [Related]
10. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
11. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
12. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry.
Shamai S; Rozenbaum Z; Merimsky O; Derakhshesh M; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Laufer-Perl M
BMC Cancer; 2020 Jun; 20(1):609. PubMed ID: 32605637
[TBL] [Abstract][Full Text] [Related]
13. Rationale and Design of the Cessation Of Pharmacotherapy In Recovered Chemotherapy-induced cardioToxicity (COP-RCT): A Pilot Study.
Yu C; Negishi T; Pathan F; Sverdlov A; Thomas L; Shirazi M; Koo CY; Tan LL; Miyazaki S; Negishi K
Heart Lung Circ; 2024 May; 33(5):753-757. PubMed ID: 37949748
[TBL] [Abstract][Full Text] [Related]
14. Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study.
Liu J; Cao Y; Zhu K; Yao S; Yuan M; Kong X; Liu X; Li Y; Cui Y; Han X; Zhou X; Meng R; Shi H
Quant Imaging Med Surg; 2022 Oct; 12(10):4771-4785. PubMed ID: 36185042
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of cancer therapy cardiotoxicity as assessed by imaging procedures: A scoping review.
Cantoni V; Green R; Assante R; D'Antonio A; Maio F; Criscuolo E; Bologna R; Petretta M; Cuocolo A; Acampa W
Cancer Med; 2023 May; 12(10):11396-11407. PubMed ID: 36999824
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
Glen C; Adam S; McDowell K; Waterston A; Tan YY; Petrie MC; Coats CJ; Lang NN
JACC CardioOncol; 2023 Oct; 5(5):628-637. PubMed ID: 37969652
[TBL] [Abstract][Full Text] [Related]
17. Early electrocardiographic indices for predicting chronic doxorubicin-induced cardiotoxicity.
Kinoshita T; Yuzawa H; Natori K; Wada R; Yao S; Yano K; Akitsu K; Koike H; Shinohara M; Fujino T; Shimada H; Ikeda T
J Cardiol; 2021 Apr; 77(4):388-394. PubMed ID: 33214049
[TBL] [Abstract][Full Text] [Related]
18. Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction.
Saijo Y; Kusunose K; Okushi Y; Yamada H; Toba H; Sata M
Heart; 2020 Nov; 106(22):1752-1758. PubMed ID: 32209616
[TBL] [Abstract][Full Text] [Related]
19. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.
Tahir E; Azar M; Shihada S; Seiffert K; Goy Y; Beitzen-Heineke A; Molwitz I; Muellerleile K; Stehning C; Schön G; Adam G; Petersen C; Müller V; Lund GK
Eur Radiol; 2022 Mar; 32(3):1853-1865. PubMed ID: 34536111
[TBL] [Abstract][Full Text] [Related]
20. Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction.
Tonry C; Russell-Hallinan A; McCune C; Collier P; Harbinson M; Dixon L; Watson CJ
Cardiovasc Res; 2023 May; 119(3):710-728. PubMed ID: 35640873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
